Decheng Capital LLC — 13F Holdings & Portfolio

CIK 2010850 · latest 13F-HR filed 2026-11-13

Decheng Capital LLC manages $685.1M in 13F-reported U.S. long-equity assets across 11 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are CGON (65.93%), NUVB (21.22%), ACRS (3.10%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 0 new positions and exited 3; 0 existing positions rose in reported value and 8 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$685.1M

Long-equity book

Holdings
11

Distinct positions

Period
2026-09-30

Filed 2026-11-13

Q/Q Activity
+0 / −3 / ↑0 / ↓8

vs 2026-06-30

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q3 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q2 26 → Q3 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

5 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 99.9%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Assets Under Management
$2.73B
Discretionary
$2.73B
Employees
23
Accounts
10
Address
3000 SAND HILL ROAD
BUILDING 2, SUITE 110
MENLO PARK, CA 94025
Phone
(650) 382-5514
Name Title / Status Ownership Type
CUI, XIANGMIN, NMN ControlMANAGING DIRECTOR
since Nov 2011
75% or moreIndividual
BAO, HONGBO, NMNCHIEF COMPLIANCE OFFICER
since Aug 2024
Less than 5%Individual
QIU, YUHENG, NMNCHIEF FINANCIAL OFFICER
since Aug 2024
Less than 5%Individual
Ownership & leadership changes · 6 filings with changes since Jul 19, 2018

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 31, 2025 filing
  • Listed againQIU, YUHENG, NMN · CHIEF FINANCIAL OFFICER · Less than 5%
Aug 14, 2024 filing
  • No longer listedQIU, YUHENG, NMN · CHIEF COMPLIANCE OFFICER · Less than 5% · listed since Oct 2023
  • AddedBAO, HONGBO, NMN · CHIEF COMPLIANCE OFFICER · Less than 5%
Mar 28, 2024 filing
  • AddedQIU, YUHENG, NMN · CHIEF COMPLIANCE OFFICER · Less than 5%
  • ChangedCUI, XIANGMIN, NMN · title MANAGING DIRECTOR; CHIEF COMPLIANCE OFFICER → MANAGING DIRECTOR
May 15, 2023 filing
  • No longer listedTSE, LAURA · CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Nov 2021
  • ChangedCUI, XIANGMIN, NMN · title MANAGING DIRECTOR → MANAGING DIRECTOR; CHIEF COMPLIANCE OFFICER
Dec 6, 2021 filing
  • AddedTSE, LAURA · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedCUI, XIANGMIN, NMN · title MANAGING DIRECTOR/CHIEF COMPLIANCE OFFICER → MANAGING DIRECTOR
Mar 30, 2020 filing
  • ChangedCUI, XIANGMIN, NMN · title MEMBER → MANAGING DIRECTOR/CHIEF COMPLIANCE OFFICER
Jul 19, 2018 filing (earliest on record)
  • ListedCUI, XIANGMIN, NMN · MEMBER · 75% or more · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

  • No increased positions.
Show all 0 →

Top Trims

Show all 8 →

New Positions

  • No new positions this quarter.
Show all 0 →

Decheng Capital LLC Holdings (2026-09-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 CG ONCOLOGY INC CGON 156944100 $451.7M 65.93% 6,371,669 SH
2 Nuvation Bio Inc. NUVB 67080N101 $145.3M 21.22% 25,954,439 SH
3 Aclaris Therapeutics, Inc. ACRS 00461U105 $21.3M 3.10% 4,041,736 SH
4 AARDVARK THERAPEUTICS INC AARD 002942100 $20.6M 3.01% 3,917,299 SH
5 Upstream Bio Inc. UPB 91678A107 $14.4M 2.10% 2,724,868 SH
6 Arcus Biosciences, Inc RCUS 03969F109 $11.0M 1.60% 425,079 SH
7 Equillium Inc. EQ 29446K106 $7.2M 1.05% 4,447,308 SH
8 Lyell Immunopharma, Inc. LYEL 55083R104 $6.8M 0.99% 692,050 SH
9 Zentalis Pharmaceuticals Inc. ZNTL 98943L107 $3.7M 0.54% 1,323,327 SH
10 BeyondSpring Inc. BYSI G10830100 $2.4M 0.34% 3,065,702 SH
11 Pyxis Oncology, Inc (formerly Apexigen) PYXS 747324101 $761.5K 0.11% 326,810 SH
Filing History
Period Filed AUM Holdings Accession
2026-09-30 2026-11-13 $685.1M 11 0001104659-26-127247
2026-06-30 2026-08-14 $731.7M 14 0001104659-26-096837
2026-03-31 2026-05-13 $661.3M 14 0001104659-26-060145
2025-12-31 2026-02-12 $743.4M 19 0001104659-26-014146
2025-09-30 2025-11-14 $573.2M 23 0001104659-25-112117
Filer Information
Address
3000 SAND HILL RD
BUILDING 2, SUITE 110
MENLO PARK, CA 94025
Phone
(650) 382-5514
Filing Manager
Decheng Capital LLC
MENLO PARK, CA
Signatory
Hongbo Bao
Chief Compliance Officer